Disclaimer: VFC has no affiliation with Cel-Sci Corp or with any third parties associated with the companies. VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog. VFC does not offer advice or investment services and nothing you read here should be construed as such. VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table. #AhYeah.
Shares of Cel-Sci Corp (CVM) are hot and in the spotlight these days after the company announced last week that the last "event," or death, necessary to complete data analysis for its global Phase III trial testing Multikine in the treatment of head and neck cancer had occurred. After nearly a decade of waiting through many peaks and valleys of trading for CVM, investors were elated that the trial results are finally on their way. There is much speculation, however, as to just how long the wait for analysis will take.
According to the press release, "The database is now being prepared for database lock. Once the database has been locked the final analysis of the trial results can be performed." A write up by Zachs a few days ago does a pretty good job of outlining which steps may take place between the last event and data release. A few of those steps could take a little bit of time, especially in the middle of this Covid19 pandemic that we are experiencing. Zachs also mentioned the possibility of the data being discussed at an upcoming conference later this year...
Click 'Read more' below to read more. First, use the link below for discounts to great backpacks and travel supplies!